// App-Quantinova.ai

P4-01-03 : Prognostic relevance of circulating tumor cells across different molecular subgroups in the adjuvant SUCCESS-A study

Researchers

Presenter

  • Janni W

Principal Investigators

  • Hberle L

  • Schochter F

  • Albrecht S

  • Jger B

  • Jckstck J

  • Fehm T

  • Mller V

  • Friese K

  • Lichtenegger W

  • Beckmann MB

  • Rack B

  • Rezai M

  • Hilfrich J

  • Tesch H

  • Heinrich G

  • Forstbauer H

  • Friedl T

  • Fasching PA

  • Schwentner L

Medical Centers

  • Schwerpunktpraxis fuer Gynaekologische Onkologie, Fuerstenwalde, Germany

  • Luisenkrankenhaus, Duesseldorf, Germany

  • Charite Berlin, Berlin, Germany

  • University of Ulm, Ulm, GermanyUniversity Hospital Ludwig-Maximilians-University, Munich, GermanyDuesseldorf University Hospital, Duesseldorf, Germany

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt/Main, Germany

  • University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMNUniversity Hospital, Erlangen, Germany

  • Haematologisch-Onkologische Schwerpunktpraxis, Troisdorf, Germany

  • Eilenriede Klinik Brustzentrum, Hannover, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

  • Body mass index

Drug/Treatment

  • Gemcitabine

  • Epirubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved